Drugs / BI 894416
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04540874 | Oct → Nov 2020 | — | Boehringer Ingelheim | Terminated | No outcome recorded |
| Phase 1 | NCT04232839 | Feb → Nov 2020 | — | Boehringer Ingelheim | Terminated | No outcome recorded |
| Phase 1 | NCT04060719 | Sep → Oct 2019 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT03971539 | Jul 2019 → Oct 2020 | asthma | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT03871595 | Mar → Apr 2019 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT03722173 | Nov → Dec 2018 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT03315936 | Nov 2017 → Sep 2018 | — | Boehringer Ingelheim | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BI 894416 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03315936 ↗ |
| Route | Oral | “following oral administration of single rising doses.” NCT03315936 ↗ |